Is Zepbound for Diabetes? What Zepbound Is, How It Works, and What It's Approved For

Is Zepbound for diabetes, or only for weight loss?

Zepbound is not FDA-approved to treat type 2 diabetes. It is not approved for type 1 diabetes either. Its label covers two uses: long-term weight management, and moderate to severe obstructive sleep apnea in adults with obesity.

That does not shut out women who have type 2 diabetes. When the FDA approved Zepbound in November 2023, it listed type 2 diabetes among the weight-related conditions that can qualify a person with overweight. So a doctor can prescribe Zepbound for weight to a woman who also has diabetes.

The FDA reviewed that exact situation before approval. SURMOUNT-2 followed 938 adults with type 2 diabetes and obesity or overweight for 72 weeks, and about half were women. Weight fell 12.8% on the 10 mg dose and 14.7% on 15 mg. People on placebo lost 3.2%.

Blood sugar improved as well. A1C is the lab number that shows your average blood sugar over about three months. In SURMOUNT-2, it started near 8% and dropped 2.1 points on either dose, against 0.5 points on placebo, according to the FDA label.

The label matters most when insurance gets involved. Plans decide coverage by approved use, so a plan that pays for diabetes drugs may still exclude weight-loss drugs. That is often why the same medicine gets prescribed under its diabetes name, Mounjaro, when diabetes is the main reason. What Zepbound costs walks through coverage and cash prices.

Zepbound for type 2 diabetes: if you already take diabetes medicine

Zepbound lowers blood sugar on its own. Combined with insulin or a sulfonylurea, an older type of diabetes pill such as glipizide, it can push blood sugar too low. The label calls this hypoglycemia and notes that severe cases can happen.

For that reason, the label says your doctor may need to lower your insulin or sulfonylurea dose when Zepbound starts. The warning signs it lists include shakiness, sweating, confusion, a fast heartbeat and sudden hunger.

The label also says not to combine Zepbound with Mounjaro or with any GLP-1 medicine, such as Ozempic, Wegovy or Trulicity. Mounjaro is the same drug, so using both would stack two doses of tirzepatide. GLP-1 medicines work on one of the same pathways.

One more note applies only to diabetes. Diabetic retinopathy is eye damage caused by high blood sugar. A fast improvement in blood sugar can briefly worsen it, so the label asks that anyone with that history be monitored.

What is Zepbound, and what is it used for?

Zepbound is Eli Lilly's brand of tirzepatide. It is a once-weekly shot you give under the skin of the belly or thigh, or that someone else gives in the back of your upper arm. It is meant to go with a lower-calorie diet and more physical activity.

The current FDA label lists two approved uses:

• Weight management, approved November 8, 2023. For adults with a BMI of 30 or more, or 27 or more plus at least one weight-related condition. Examples include high blood pressure, high cholesterol and type 2 diabetes. BMI, or body mass index, compares your weight with your height.
• Obstructive sleep apnea, approved December 20, 2024. For moderate to severe sleep apnea in adults with obesity. In sleep apnea, the airway keeps closing during sleep and breathing pauses. The FDA called Zepbound the first drug treatment for this condition.

Zepbound now comes in four formats on the label. There is a single-dose pen, a single-dose vial, a multi-dose vial and a KwikPen. The multi-dose vial and the KwikPen each hold four weekly doses.

No other use is on the label as of its September 2026 update. Lilly withdrew a request to add heart failure in 2025, after the FDA asked for another trial. Zepbound also has no heart-risk approval, which the benefits section below explains.

Zepbound vs Mounjaro: same drug, different label

Mounjaro and Zepbound contain the same tirzepatide, made by the same company. The difference is the approved use printed on the label, which shapes who gets which one.

Mounjaro is approved to lower blood sugar in type 2 diabetes, for adults and for children 10 and older. Since August 28, 2026, it is also approved to cut the risk of heart attack, stroke and heart-related death in adults with type 2 diabetes at high risk. Zepbound has neither use on its label.

Price and insurance usually decide the rest. Mounjaro vs. Zepbound compares what each one costs and which one a plan is likelier to cover.

What is in Zepbound?

The main ingredient in Zepbound is tirzepatide. It is a lab-made peptide, a short chain of amino acids, modeled on a gut hormone called GIP. A fatty side chain lets it hitch a ride on a blood protein, which keeps it working for a full week.

The inactive ingredients depend on the format you get. Here is what the FDA label lists:

• Single-dose pen and single-dose vial: sodium chloride, sodium phosphate and water for injection. Nothing else is listed.
• KwikPen and multi-dose vial: the same base, plus benzyl alcohol, phenol and glycerin. Benzyl alcohol and phenol are preservatives, which a pen or vial used four times needs.
• Every format: a small amount of hydrochloric acid or sodium hydroxide may be added to adjust acidity.

Compounded tirzepatide is not Zepbound. A pharmacy mixes it, and the FDA has not approved it or reviewed its safety and quality. Can you compound Zepbound online? explains what you would actually be buying.

How does Zepbound work?

After a meal, your gut releases two hormones called GIP and GLP-1. Both help signal that you have eaten and help your body handle sugar. Zepbound switches on the receptors for both, which is why it is called a dual agonist.

The FDA label says Zepbound mainly works by cutting how much you eat, most likely by turning down appetite. It also slows how fast food leaves your stomach. It releases insulin only when blood sugar is high, lowers glucagon, a hormone that raises blood sugar, and helps your body respond better to insulin.

Weight comes off because you eat less over many months, not because fat is burned away. The deeper receptor science lives in how tirzepatide works.

What are the benefits of Zepbound beyond weight loss?

Weight is still the headline result. SURMOUNT-1 tested Zepbound for 72 weeks in 2,539 adults without diabetes. About 68% were women, and their average age was 45.

Average weight loss was 15.0% on 5 mg, 19.5% on 10 mg and 20.9% on 15 mg. People on placebo lost 3.1%, according to the trial published in the New England Journal of Medicine in 2022.

Sleep apnea

Sleep apnea is measured by the apnea-hypopnea index, or AHI. It counts the breathing pauses and shallow breaths per hour of sleep. In the two SURMOUNT-OSA trials, published in the New England Journal of Medicine in 2024, people started near 50 events an hour.

In people not using a breathing machine, AHI fell by about 25 events an hour on Zepbound, against about 5 on placebo. In people using a CPAP machine, a mask that keeps the airway open at night, it fell by about 29 events, against about 5 on placebo.

After one year, 42% reached remission or mild sleep apnea without daytime sleepiness in the trial without CPAP, and 50% in the trial with CPAP. On placebo, it was 16% and 14%, according to the FDA label.

Blood pressure, cholesterol and blood sugar

The FDA label reports these from SURMOUNT-1 at 72 weeks. Systolic blood pressure, the top number, fell about 7 points on Zepbound, against 1 point on placebo.

Non-HDL cholesterol, the sum of the harmful types, fell 8% to 12%, against 2% on placebo. HDL, the protective type, rose 7% to 9%, while it barely moved on placebo.

A1C started at an average of 5.6% in this trial without diabetes. It fell 0.4 points on Zepbound, against 0.1 points on placebo.

Heart protection is not on the Zepbound label

Zepbound has no FDA approval to lower the risk of heart attack or stroke. SURMOUNT-MMO is testing exactly that in about 15,000 people with obesity and no diabetes, and it is still running. The only tirzepatide heart approval belongs to Mounjaro, for adults with type 2 diabetes at high risk.

Is Zepbound right for a woman in perimenopause or menopause?

Many women first cross the eligibility line in their 40s or 50s. Falling estrogen moves fat toward the belly and makes the body respond less to insulin, even when habits have not changed.

You do not need diabetes to qualify. A BMI of 30, or 27 with high blood pressure or high cholesterol, is enough under the label. Zepbound also improves insulin response, the very thing midlife tends to erode, though no trial has studied menopausal women as a separate group.

Sleep apnea becomes more common after menopause. In women it often shows up as fatigue, morning headaches or poor sleep rather than loud snoring. If that sounds familiar, a sleep study can confirm it, and Zepbound's second approval may then apply.

Muscle is the trade-off to watch. The FDA label notes that tirzepatide removes more fat than lean mass, but some muscle still goes. Estrogen loss already speeds muscle decline, so protein and strength training matter more now. GLP-1s and muscle loss in perimenopause covers what protects it.

Menopause hormone therapy and Zepbound do different jobs. Hormone therapy treats symptoms like hot flashes, while Zepbound works on appetite and weight. Nothing on the Zepbound label rules out using both. Our GLP-1 and menopause guide explains how they fit together.

Hormone therapy is not a heart medicine, though. The FDA and The Menopause Society do not recommend it to prevent heart disease.

Zepbound and birth control

If you still take the pill in perimenopause, this part matters. Zepbound slows stomach emptying, which can make birth control pills work less well. The label advises switching to a non-oral method, or adding a barrier method such as condoms.

Do this for 4 weeks after starting and for 4 weeks after each dose increase. Patches, rings, IUDs and implants should not be affected, per the label. Pregnancy is still possible in perimenopause, as our perimenopause pregnancy guide explains.

Whether the same delay affects oral progesterone taken with hormone therapy has not been studied. A 2026 review in the journal Maturitas called it possible but unproven.

Who should not take Zepbound?

Zepbound carries a boxed warning, the FDA's strongest kind. In rats, tirzepatide caused thyroid C-cell tumors. It is not known whether this happens in people. The current label lists these limits:

• Thyroid cancer history: do not use Zepbound if you or a family member has had medullary thyroid carcinoma, a rare thyroid cancer. The same applies if you have MEN 2, an inherited syndrome that causes gland tumors.
• Serious allergy: do not use it after a serious allergic reaction to tirzepatide or any of its ingredients.
• Pregnancy: stop Zepbound once pregnancy is confirmed. Weight loss offers no benefit in pregnancy and may harm the baby.
• Pancreatitis: stop and call your doctor for severe belly pain that will not go away, sometimes spreading to the back.
• Severe gastroparesis: Zepbound is not recommended if your stomach already empties very slowly.
• Surgery or sedation: tell every provider you take it. Food can stay in the stomach and reach the lungs under anesthesia.
• Gallbladder and kidneys: gallbladder problems have occurred. Dehydration from vomiting or diarrhea can also strain the kidneys.

What to expect once you start Zepbound

Everyone starts at 2.5 mg once a week for 4 weeks. The dose then rises in 2.5 mg steps, at least 4 weeks apart, toward a maintenance dose. The full ladder is in the Zepbound dosage guide.

Stomach side effects are the most common, and most happen while the dose is rising. In the label's weight trials, nausea affected 25% to 29% of people on Zepbound, against 8% on placebo.

Diarrhea affected 19% to 23%, against 8% on placebo. Vomiting, constipation and indigestion were also more frequent, and most of these eased over time. Zepbound side effects covers the full list and which symptoms need a prompt call.

Results build over months, not weeks, as Zepbound results shows with a realistic timeline. Smaller meals with enough protein help with both nausea and muscle. The Zepbound diet guide shows what that looks like on a plate.